At the 44th Annual J.P. Morgan Healthcare Conference, ANI Pharmaceuticals’ CEO Nikhil Lalwani and CFO Steve Carey outlined a strategic transformation into a leading rare disease company. Management reiterated guidance for over $1 billion in 2026 revenues, reflecting year-over-year growth of 26% compared with 2025. The rare disease segment is expected to account for roughly 60% of total sales, driven by the launch and market expansion of purified Cortrophin Gel, which is positioned to deliver durable, multiyear growth. Meanwhile, the established generics business will continue generating strong cash flow—supported by U.S. manufacturing and robust R&D capabilities—funding further investment in rare disease assets.

ANI closed 2025 with robust financial performance and issued guidance calling for revenues of $1.055 billion to $1.115 billion in 2026, implying approximately 60% growth over the prior year. The company forecasts purified Cortrophin Gel sales of $540 million to $575 million next year, underpinned by the addition of a 90-person commercial team and the upcoming pivotal Phase 4 trial. With an EBITDA margin expected to expand on higher-margin rare disease products and no anticipated cash burn, ANI enters 2026 with $285 million in cash on hand and ample debt capacity.

ANI shares jumped 10.6% in the latest trading session on volume notably above its 30-day average, as analysts revised earnings estimates higher for both 2025 and 2026. Despite the bullish analyst sentiment, some strategists caution that valuation—currently standing at 11.2x forward P/E, a 43% discount to peers—leaves limited upside if execution on the Cortrophin Gel launch or Phase 4 trial timelines slip. Investors will be watching upcoming quarterly results and pipeline milestones for confirmation of the company’s growth story.